Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 2/20 | 0.35 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.32 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.32 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.31 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29195406 | 0.94 | TYMP (0.37) | TYMPP2RY6P2RY14NT5EP2RY2 | |
| SCHEMBL667613 | 0.94 | TYMP (0.37) | TYMPP2RY6P2RY14NT5EP2RY2 | |
| SCHEMBL26535949 | 0.94 | TYMP (0.37) | TYMPP2RY6P2RY14NT5EP2RY2 | |
| SCHEMBL3915198 | 0.94 | TYMP (0.37) | TYMPP2RY6P2RY14NT5EP2RY2 | |
| SCHEMBL13715722 | 0.94 | TYMP (0.37) | TYMPP2RY6P2RY14NT5EP2RY2 | |
| SCHEMBL24878606 | 0.94 | TYMP (0.37) | TYMPP2RY6P2RY14NT5EP2RY2 | |
| SCHEMBL31229956 | 0.94 | TYMP (0.37) | TYMPP2RY6P2RY14NT5EP2RY2 | |
| SCHEMBL12765879 | 0.92 | TYMP (0.34) | TYMPP2RY6P2RY14NT5EP2RY2 | |
| SCHEMBL16315472 | 0.92 | TYMP (0.34) | TYMPP2RY6P2RY2P2RY4 | |
| SCHEMBL6518721 | 0.92 | TYMP (0.35) | TYMPP2RY6P2RY14NT5EP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109863161-B | Labeled polynucleotides useful for nucleic acid sequencing | 豪夫迈·罗氏有限公司 | 2022-06-03 | — | — | CN | claimed |
| US-20260117285-A1 | COMPOSITIONS AND METHODS FOR IMPROVING LIBRARY ENRICHMENT | ILLUMINA INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12473594-B2 | Chemical tagging-based method for modified nucleoside sequencing, enrichment, and measurement | PEKING UNIVERSITY (CN) | 2025-11-18 | — | — | US | disclosed |
| US-12435362-B2 | Compositions and methods for improving library enrichment | ILLUMINA, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| CN-112955568-B | Compositions and methods for improving library enrichment | ILLUMINA公司 | 2025-05-16 | — | — | CN | disclosed |
| US-20240264142-A1 | MOLECULAR DETECTION AND COUNTING USING NANOPORES | ROCHE SEQUENCING SOLUTIONS INC (US) | 2024-08-08 | — | — | US | disclosed |
| US-20230332219-A1 | CHEMICAL TAGGING-BASED METHOD FOR MODIFIED NUCLEOSIDE SEQUENCING, ENRICHMENT, AND MEASUREMENT | PEKING UNIVERSITY (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230323343-A1 | CLOSED LINEAR DNA WITH MODIFIED NUCLEOTIDES | TYRIS THERAPEUTICS, S.L. (ES) | 2023-10-12 | — | — | US | disclosed |
| CN-110603330-B | Oligonucleotide derivative or salt thereof | 协和麒麟株式会社 | 2023-09-05 | — | — | CN | disclosed |
| EP-3617314-B1 | OLIGONUCLEOTIDE DERIVATIVE OR SALT THEREOF | KYOWA KIRIN CO LTD (JP) | 2023-02-15 | — | — | EP | disclosed |
| US-20060223770-A1 | IRNA agents targeting VEGF | ALNYLAM EUROPE AG (DE) | 2006-10-05 | — | — | US | disclosed |
| US-20060217330-A1 | Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs | BANK OF AMERICA, N.A. | 2006-09-28 | — | — | US | disclosed |
| US-20060094032-A1 | iRNA agents targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. | 2006-05-04 | — | — | US | disclosed |
| US-20050267300-A1 | Processes and reagents for oligonucleotide synthesis and purification | ALNYLAM PHARMACEUTICALS | 2005-12-01 | — | — | US | disclosed |
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | SIRNA THERAPEUTICS, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| US-6686463-B2 | FEWER SYNTHETIC STEPS; INVOLVES FORMATION OF A 5',4'-BRIDGING SILYL PROTECTING GROUP TO FORM A FUSED SILOXANE ON THE FURAN RING | SIRNA THERAPEUTICS, INC. | 2004-02-03 | — | — | US | disclosed |
| EP-1313752-A2 | METHODS FOR SYNTHESIZING NUCLEOSIDES, NUCLEOSIDE DERIVATIVES AND NON-NUCLEOSIDE DERIVATIVES | RIBOZYME PHARMACEUTICALS, INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | RIBOZYME PHARMACEUTICALS, INC. | 2002-10-17 | — | — | US | disclosed |
| US-20020120129-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | RIBOZYME PHARMACEUTICALS, INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002018405-A2 | METHODS FOR SYNTHESIZING NUCLEOSIDES, NUCLEOSIDE DERIVATIVES AND NON-NUCLEOSIDE DERIVATIVES | RIBOZYME PHARMACEUTICALS, INCORPORATED (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094032-A1 | iRNA agents targeting VEGF | KDR, FLT4, SNRPE | TYMP 1464/4885P2RY6 4719/4885P2RY14 4836/4885 |
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | TYMP 16/4885P2RY6 712/4885P2RY14 694/4885 |
| US-20230332219-A1 | CHEMICAL TAGGING-BASED METHOD FOR MODIFIED NUCLEOSIDE SEQUENCING, ENRICHMENT, AND MEASUREMENT | NT5C3B, BHMT2, NNMT | TYMP 90/4885P2RY6 1712/4885P2RY14 3446/4885 |
| US-12473594-B2 | Chemical tagging-based method for modified nucleoside sequencing, enrichment, and measurement | NT5C3B, BHMT2, NNMT | TYMP 90/4885P2RY6 1712/4885P2RY14 3446/4885 |
| US-20020120129-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | TYMP 17/4885P2RY6 700/4885P2RY14 854/4885 |
| US-20060223770-A1 | IRNA agents targeting VEGF | KDR, FLT4, SNRPE | TYMP 1464/4885P2RY6 4719/4885P2RY14 4836/4885 |
| US-20260117285-A1 | COMPOSITIONS AND METHODS FOR IMPROVING LIBRARY ENRICHMENT | TTI1, MBNL1, UPF1 | TYMP 94/4885P2RY6 1453/4885P2RY14 1603/4885 |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | TYMP 14/4885P2RY6 862/4885P2RY14 799/4885 |
| US-20050267300-A1 | Processes and reagents for oligonucleotide synthesis and purification | RNGTT, ALKBH1, MTAP | TYMP 26/4885P2RY6 328/4885P2RY14 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.